COVID-19: ACT trials for colchicine and antithrombotic therapies
- PMID: 36228642
- PMCID: PMC9550192
- DOI: 10.1016/S2213-2600(22)00368-X
COVID-19: ACT trials for colchicine and antithrombotic therapies
Conflict of interest statement
We declare no competing interests.
Comment on
-
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.Lancet Respir Med. 2022 Dec;10(12):1160-1168. doi: 10.1016/S2213-2600(22)00299-5. Epub 2022 Oct 10. Lancet Respir Med. 2022. PMID: 36228639 Free PMC article. Clinical Trial.
-
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.Lancet Respir Med. 2022 Dec;10(12):1169-1177. doi: 10.1016/S2213-2600(22)00298-3. Epub 2022 Oct 10. Lancet Respir Med. 2022. PMID: 36228641 Free PMC article. Clinical Trial.
References
-
- Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022 doi: 10.1016/S2213-2600(22)00298-3. published online Oct 10. - DOI - PMC - PubMed
-
- Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19) https://ourworldindata.org/coronavirus
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
